Evidence map›Paper›PMID 26098450›Full record

ArticleNature biotechnology2015

Lineage conversion induced by pluripotency factors involves transient passage through an iPSC stage.

Ori Bar-Nur, Cassandra Verheul, Andreia G Sommer, Justin Brumbaugh, Benjamin A Schwarz, Inna Lipchina, Aaron J Huebner, Gustavo Mostoslavsky, Konrad Hochedlinger

Open access · greenAbstract read
In one paragraph

Article in Nature biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Context-dependent roles of YAP/TAZ in stem cell fates and cancer.Cellular and molecular life sciences : CMLS · 2021
    Review
  15. Article
  16. Article
  17. The Future of Direct Cardiac Reprogramming: AnyInternational journal of molecular sciences · 2020
    Review
  18. Article
  19. Article
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Ori Bar-Nur1] Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [3] Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA. [4] Howard Hughes Medical Institute, Chevy Chase, Maryland, USA. [5] Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
Cassandra Verheul1] Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [3] Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA. [4] Howard Hughes Medical Institute, Chevy Chase, Maryland, USA. [5] Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
Andreia G Sommer1] Center for Regenerative Medicine (CReM), Boston University School of Medicine, Boston, Massachusetts, USA. [2] Boston Medical Center, Boston, Massachusetts, USA.
Justin Brumbaugh1] Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [3] Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA. [4] Howard Hughes Medical Institute, Chevy Chase, Maryland, USA. [5] Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
Benjamin A Schwarz1] Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [3] Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA. [4] Howard Hughes Medical Institute, Chevy Chase, Maryland, USA. [5] Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
Inna Lipchina1] Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [3] Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA. [4] Howard Hughes Medical Institute, Chevy Chase, Maryland, USA. [5] Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
Aaron J Huebner1] Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [3] Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA. [4] Howard Hughes Medical Institute, Chevy Chase, Maryland, USA. [5] Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
Gustavo Mostoslavsky1] Center for Regenerative Medicine (CReM), Boston University School of Medicine, Boston, Massachusetts, USA. [2] Boston Medical Center, Boston, Massachusetts, USA.
Konrad Hochedlinger1] Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [3] Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA. [4] Howard Hughes Medical Institute, Chevy Chase, Maryland, USA. [5] Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
Harvard University · USBoston Medical Center · USHarvard Stem Cell Institute · USHoward Hughes Medical Institute · USMassachusetts General Hospital · US

Funding

MOLECULAR IMMUNOLOGY AND TUMOR BIOLOGYT32CA009216 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Michael Langenau · 1985 to 2026
$10.6M
Transcription Factor Induced ReprogrammingR01HD058013 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI HOCHEDLINGER, KONRAD · 2010 to 2019
$4.4M
The regulatory role of chromatin interaction in pluripotency and differentiationF32HD078029 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI BRUMBAUGH, JUSTIN · 2014 to 2016
$175k
Identifying regulators of the naive and primed pluripotent stateF32HD079225 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI LIPCHINA, INNA · 2014 to 2016
$169k
Howard Hughes Medical InstituteNCI NIH HHS 5-T32-CA-9216-33NCI NIH HHS T32 CA009216NICHD NIH HHS 1F32HD078029-01A1NICHD NIH HHS 1F32HD079225-01A1NICHD NIH HHS F32 HD078029NICHD NIH HHS F32 HD079225NICHD NIH HHS R01 HD058013NICHD NIH HHS R01HD058013
6 · The paper itself

Abstract

Brief expression of pluripotency-associated factors such as Oct4, Klf4, Sox2 and c-Myc (OKSM), in combination with differentiation-inducing signals, has been reported to trigger transdifferentiation of fibroblasts into other cell types. Here we show that OKSM expression in mouse fibroblasts gives rise to both induced pluripotent stem cells (iPSCs) and induced neural stem cells (iNSCs) under conditions previously shown to induce only iNSCs. Fibroblast-derived iNSC colonies silenced retroviral transgenes and reactivated silenced X chromosomes, both hallmarks of pluripotent stem cells. Moreover, lineage tracing with an Oct4-CreER labeling system demonstrated that virtually all iNSC colonies originated from cells transiently expressing Oct4, whereas ablation of Oct4(+) cells prevented iNSC formation. Lastly, an alternative transdifferentiation cocktail that lacks Oct4 and was reportedly unable to support induced pluripotency yielded iPSCs and iNSCs carrying the Oct4-CreER-derived lineage label. Together, these data suggest that iNSC generation from fibroblasts using OKSM and other pluripotency-related reprogramming factors requires passage through a transient iPSC state.

Indexed as

AnimalsCells, CulturedCell TransdifferentiationFemaleFibroblastsGene SilencingInduced Pluripotent Stem CellsKruppel-Like Factor 4MaleMiceMice, TransgenicTranscription FactorsTransgenesKlf4 protein, mouseKruppel-Like Factor 4Transcription Factors

Identifiers

PMID26098450
PMCPMC4840929
OpenAlexW1587178402

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.